Russell A. Chorush

Dr. Russell A. Chorush is a founding partner at Heim, Payne & Chorush, LLP, specializing in patent infringement and intellectual property-related antitrust litigation, particularly within high-technology sectors and pharmaceutics. His technical expertise spans electronics, chemicals, microprocessors, computer architecture, memory control systems, telecommunications, and semiconductor manufacturing processes. He also has significant experience with Hatch-Waxman Act and reverse-payment pharmaceutical antitrust cases, involving products such as Namenda®, Provigil®, and K-Dur®.

Chorush represents both plaintiffs and defendants, demonstrating a balanced litigation practice. His firm has a track record of representing patent owners in asserting their intellectual property, as seen in cases such as Advanced Integrated Circuit Process LLC v. Taiwan Semiconductor Manufacturing Company, Ltd., where he served as counsel for the plaintiff. He has also defended patent owners in litigation against alleged infringers and in post-grant challenges. In the pharmaceutical sector, he has notably represented plaintiffs, including securing a $60.2 million settlement in the In re K-Dur Antitrust Litigation for direct purchasers against Merck & Co., a case that influenced the U.S. Supreme Court's FTC v. Actavis Inc. decision. He is credited with achieving recoveries well in excess of $2 billion for clients and prevailing in all cases he has tried to final decision.

Chorush is active in post-grant proceedings, as evidenced by his appearances in multiple Unified Patents v. Advanced Integrated Circuit Process LLC cases, defending patents at the Patent Trial and Appeal Board (PTAB). He has been recognized in the Patexia PTAB Intelligence Report as a top-performing and most active attorney for 2026. He holds a Ph.D. in Chemistry from Cornell University (1994) and a J.D., summa cum laude, from the University of Houston Law Center (2001), where he was valedictorian and achieved the top score on the Texas State Bar examination. He is admitted to practice in Texas, before the U.S. Supreme Court, the U.S. Court of Appeals for the Federal Circuit, and the U.S. Patent & Trademark Office.